A
A. K. Srivastava
Researcher at Central Drug Research Institute
Publications - 53
Citations - 1436
A. K. Srivastava is an academic researcher from Central Drug Research Institute. The author has contributed to research in topics: Glycosyl & Docking (molecular). The author has an hindex of 18, co-authored 49 publications receiving 1345 citations. Previous affiliations of A. K. Srivastava include Academy of Scientific and Innovative Research.
Papers
More filters
Journal ArticleDOI
Erratum to “Next Generation Sequencing: Potential and Application in Drug Discovery”.
Navneet Kumar Yadav,Pooja Shukla,Ankur Omer,Shruti Pareek,A. K. Srivastava,F. W. Bansode,R. K. Singh +6 more
TL;DR: Through this erratum the authors declare that two coauthors were missing in the article entitled “Next generation sequencing: potential and application in drug discovery”.
Journal ArticleDOI
Synthesis and antihyperglycemic activity of chalcone based aryloxypropanolamines.
TL;DR: Among them compounds 5a, g, m, o, p and r showed significant reduction in blood glucose levels in both SLM and STZ animal models.
Journal ArticleDOI
Antihyperglycemic and antidyslipidemic agent from Aegle marmelos
Tadigoppula Narender,Shweta Shweta,Priti Tiwari,K. Papi Reddy,Tanvir Khaliq,Philip Prathipati,Anju Puri,A. K. Srivastava,Ramesh Chander,S.C. Agarwal,Kanwal Raj +10 more
TL;DR: The reasonable mapping of compound 2 to validated pharmacophoric hypothesis and 3D QSAR model with an estimated activity suggest that the compound 2 might be a beta(3)-AR agonist.
Journal ArticleDOI
Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity.
TL;DR: The triterpenoid 4 lowered the blood glucose levels by 18.2% and 25.0% in sucrose challenged streptozotocin induced diabetic rats (STZ-S) model at the dose of 100mg/kg body weight.
Journal ArticleDOI
Application of click chemistry towards an efficient synthesis of 1,2,3-1H-triazolyl glycohybrids as enzyme inhibitors.
TL;DR: An efficient synthesis of novel 1,2,3-1H-triazolyl glycohybrids with two or more than two sugar units or a chromenone moiety via copper-catalysed azide-alkyne cycloaddition (CuAAC) with promising inhibitory activities against α-glucosidase, glycogen phosphorylase and glucose-6-phosphatase inhibitsory activities is described.